NanoDimension Inc. lowered its position in Icosavax, Inc. (NASDAQ:ICVX – Get Rating) by 2.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,693,772 shares of the company's stock after selling 56,222 shares during the period. Icosavax accounts for 41.6% of NanoDimension Inc.'s portfolio, making the stock its largest holding. NanoDimension Inc. owned 0.07% of Icosavax worth $18,964,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ICVX. Allspring Global Investments Holdings LLC bought a new stake in Icosavax during the fourth quarter worth approximately $138,000. New York State Common Retirement Fund boosted its position in Icosavax by 36.7% during the fourth quarter. New York State Common Retirement Fund now owns 8,340 shares of the company's stock worth $191,000 after purchasing an additional 2,240 shares during the period. ProShare Advisors LLC bought a new stake in Icosavax during the fourth quarter worth approximately $201,000. JPMorgan Chase & Co. boosted its position in Icosavax by 67.6% during the first quarter. JPMorgan Chase & Co. now owns 19,548 shares of the company's stock worth $138,000 after purchasing an additional 7,883 shares during the period. Finally, Swiss National Bank bought a new stake in Icosavax during the fourth quarter worth approximately $597,000. Institutional investors and hedge funds own 79.43% of the company's stock.
Get Icosavax alerts:Analyst Ratings Changes
Separately, Evercore ISI raised Icosavax from an "in-line" rating to an "outperform" rating and set a $18.00 target price for the company in a research report on Wednesday, June 29th.
Insider Activity
In other news, insider Douglas Holtzman sold 9,337 shares of the stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $61,997.68. Following the completion of the sale, the insider now directly owns 293,711 shares of the company's stock, valued at $1,950,241.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Douglas Holtzman sold 9,337 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $61,997.68. Following the completion of the transaction, the insider now directly owns 293,711 shares of the company's stock, valued at $1,950,241.04. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam K. Simpson sold 7,017 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.64, for a total value of $46,592.88. Following the completion of the transaction, the chief executive officer now directly owns 293,772 shares of the company's stock, valued at $1,950,646.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,706 shares of company stock valued at $159,363. 39.09% of the stock is owned by company insiders.Icosavax Stock Performance
Shares of ICVX traded up $0.41 during mid-day trading on Wednesday, hitting $6.06. The company's stock had a trading volume of 2,154 shares, compared to its average volume of 113,413. Icosavax, Inc. has a one year low of $4.00 and a one year high of $41.98. The firm has a market capitalization of $241.67 million and a PE ratio of -2.11. The stock's 50-day moving average is $7.67 and its two-hundred day moving average is $9.81.
About Icosavax
(Get Rating)
Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial.
Featured Stories
- Get a free copy of the StockNews.com research report on Icosavax (ICVX)
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
- Will the Real Palantir Please Stand Up?
- Foot Locker Just Because A Very Tempting Buy
Want to see what other hedge funds are holding ICVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icosavax, Inc. (NASDAQ:ICVX – Get Rating).
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.